Enzymatic Inactivation of Antibiotics

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

Bacterial enzymes inactivate antibiotics through hydrolysis, group transfer, or redox chemistry, altering the drug before it reaches its target.
Select confirmatory tests such as phenotypic detection or molecular assays based on the suspected enzyme family and the organism isolated.
Enzyme-based resistance is only one mechanism, and phenotypic results may reflect multiple concurrent resistance pathways.

At a Glance

Enzyme Family	Primary Substrates	Mechanism	Typical Organisms	Laboratory Detection
Beta-lactamases	Penicillins, cephalosporins, carbapenems, monobactams	Hydrolysis of the beta-lactam ring	Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii	Carba NP test, modified carbapenem inactivation method, disk approximation tests
Aminoglycoside-modifying enzymes	Aminoglycosides	Acetylation, adenylation, or phosphorylation of hydroxyl or amino groups	Enterococci, staphylococci, Gram-negative bacilli	Phenotypic resistance patterns, genotypic assays
Chloramphenicol acetyltransferases	Chloramphenicol	Acetylation of the drug, preventing ribosomal binding	Staphylococci, Enterobacterales	Disk diffusion resistance, enzyme activity assays
Macrolide esterases and transferases	Macrolides, lincosamides, streptogramins	Hydrolysis or nucleotidylation of the macrocyclic ring	Gram-positive cocci, some Gram-negative species	Inducible resistance testing, genotypic detection
Tetracycline-inactivating enzymes	Tetracyclines	Oxidation or hydroxylation of the tetracycline scaffold	Bacteroides species, some Enterobacterales	Phenotypic resistance patterns, genotypic assays
Rifampicin ADP-ribosyltransferases	Rifampicin	ADP-ribosylation of the rifampicin core	Mycobacterium species, some Gram-negative	Rifampicin susceptibility testing, genotypic detection

The Problem of Enzymatic Inactivation in Antimicrobial Resistance

Antimicrobial resistance is a global public health threat that complicates the treatment of bacterial infections. The World Health Organization identifies antimicrobial resistance as a process by which bacteria change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. Among the many resistance mechanisms bacteria employ, enzymatic inactivation is one of the most clinically significant because it directly destroys or modifies the antibiotic molecule before it can act on its bacterial target.

Enzymatic inactivation occurs when bacterial enzymes chemically alter an antibiotic, rendering it ineffective. This mechanism is distinct from other resistance strategies such as target modification, efflux pumps, or reduced membrane permeability. In enzymatic inactivation, the antibiotic itself is the substrate for the enzyme, and the chemical modification prevents the drug from binding to its intended bacterial target. Understanding these enzymes is essential for laboratory professionals who must interpret antimicrobial susceptibility testing results and select appropriate confirmatory tests.

The clinical laboratory plays a central role in detecting enzymatic resistance. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing context that guides how laboratories determine minimum inhibitory concentrations and interpret resistance phenotypes. When a laboratory observes an unusual resistance pattern, the next step is often to determine whether an inactivating enzyme is responsible. This determination affects patient management, infection control decisions, and the choice of confirmatory testing.

Core Principles of Enzymatic Antibiotic Inactivation

Enzymatic inactivation of antibiotics operates through three principal chemical strategies. The first strategy is hydrolysis, where the enzyme cleaves a critical bond in the antibiotic molecule. The second strategy is group transfer, where the enzyme transfers a chemical group such as acetyl, adenyl, or phosphoryl to the antibiotic. The third strategy is redox modification, where the enzyme oxidizes or reduces the antibiotic molecule.

Each strategy produces a chemically modified antibiotic that no longer binds effectively to its bacterial target. The modified antibiotic may also be more readily expelled from the bacterial cell or may be less able to penetrate the bacterial membrane. The net result is the same, the antibiotic loses its antimicrobial activity, and the bacterium survives in the presence of the drug.

The genes encoding these enzymes are often located on mobile genetic elements such as plasmids and transposons. This mobility allows resistance genes to spread between bacterial species and across geographic regions. The World Health Organization notes that antimicrobial resistance is a natural phenomenon that is accelerated by the misuse and overuse of antimicrobials in humans, animals, and plants. The spread of enzyme-encoding genes is a major driver of the global resistance problem.

Laboratory professionals must understand the biochemical basis of these enzymes to select appropriate confirmatory tests. For example, a laboratory that observes a carbapenem-resistant Enterobacterales isolate must determine whether the resistance is due to a carbapenemase enzyme or to other mechanisms such as porin loss combined with cephalosporinase production. The distinction matters because carbapenemase-producing organisms require different infection control measures and treatment approaches.

Beta-Lactamases and Their Clinical Significance

Beta-lactamases are the most clinically important family of antibiotic-inactivating enzymes. These enzymes hydrolyze the beta-lactam ring that is shared by penicillins, cephalosporins, carbapenems, and monobactams. The hydrolysis opens the ring and destroys the antibiotic activity. Beta-lactamases are produced by a wide range of Gram-positive and Gram-negative bacteria.

The classification of beta-lactamases is based on both structural and functional characteristics. The Ambler classification divides beta-lactamases into four classes based on amino acid sequence. Class A, C, and D enzymes use a serine residue in their active site, while class B enzymes are metallo-beta-lactamases that require zinc for their activity. This structural distinction is important because it affects the susceptibility of the enzyme to inhibitors such as clavulanic acid, tazobactam, and avibactam.

The clinical significance of beta-lactamases varies by enzyme type and the organism producing it. Extended-spectrum beta-lactamases (ESBLs) hydrolyze penicillins, first, second, and third-generation cephalosporins, and aztreonam, but they are inhibited by clavulanic acid. Carbapenemases hydrolyze carbapenems, which are often the last-resort antibiotics for treating infections caused by multidrug-resistant Gram-negative bacteria. The detection of carbapenemases is a critical laboratory function because it guides both treatment and infection control decisions.

Laboratory detection of beta-lactamases requires a combination of phenotypic and genotypic methods. Phenotypic methods include the disk approximation test, the double-disk synergy test, and the carbapenem inactivation method. Genotypic methods include polymerase chain reaction (PCR) and whole-genome sequencing. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing context that helps laboratories determine which methods are appropriate for their setting.

The choice of confirmatory test depends on the organism and the suspected enzyme. For example, a laboratory that identifies an Escherichia coli isolate with resistance to ceftriaxone and ceftazidime may perform a phenotypic confirmatory test for ESBL production. If the isolate is also resistant to carbapenems, the laboratory may perform a carbapenemase detection test. The results of these tests inform the clinical microbiology report and guide the selection of therapeutic options.

Aminoglycoside Modifying Enzymes

Aminoglycoside modifying enzymes are a family of enzymes that inactivate aminoglycoside antibiotics through three distinct chemical reactions. The first reaction is acetylation, where an acetyl group is transferred to an amino group on the aminoglycoside molecule. The second reaction is adenylation, where an adenyl group is transferred to a hydroxyl group. The third reaction is phosphorylation, where a phosphoryl group is transferred to a hydroxyl group. Each of these reactions modifies the aminoglycoside molecule so that it cannot bind effectively to the bacterial ribosome.

The genes encoding aminoglycoside modifying enzymes are often located on mobile genetic elements, which facilitates their spread among bacterial populations. These enzymes are found in both Gram-positive and Gram-negative bacteria, including staphylococci, enterococci, and Enterobacterales. The clinical significance of these enzymes is that they confer resistance to aminoglycosides such as gentamicin, tobramycin, and amikacin, which are important agents for treating serious infections.

Laboratory detection of aminoglycoside modifying enzymes is primarily based on phenotypic susceptibility testing. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing context that helps laboratories determine the minimum inhibitory concentration of aminoglycosides for a given isolate. A laboratory may observe that an isolate is resistant to gentamicin but susceptible to amikacin, which suggests the presence of a specific modifying enzyme that targets gentamicin but not amikacin.

The interpretation of aminoglycoside susceptibility results requires an understanding of the enzyme substrate profiles. Some enzymes modify only one aminoglycoside, while others modify multiple agents. For example, an enzyme that acetylates gentamicin may not affect amikacin, while an enzyme that phosphorylates amikacin may also affect other aminoglycosides. This substrate specificity is important for selecting the appropriate confirmatory test and for predicting the clinical utility of different aminoglycosides.

Chloramphenicol Acetyltransferases

Chloramphenicol acetyltransferases are enzymes that inactivate chloramphenicol by transferring an acetyl group from acetyl-coenzyme A to the chloramphenicol molecule. The acetylated chloramphenicol cannot bind to the bacterial ribosome, and the antibiotic loses its activity. These enzymes are found in a wide range of bacteria, including staphylococci, Enterobacteriaceae, and other Gram-negative organisms.

The genes encoding chloramphenicol acetyltransferases are often located on plasmids, which allows them to spread among bacterial populations. The enzymes are typically inducible, meaning that the presence of chloramphenicol in the environment triggers the production of the enzyme. This inducibility is important for laboratory testing because it affects the interpretation of susceptibility results.

Laboratory detection of chloramphenicol acetyltransferases is primarily based on phenotypic susceptibility testing. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing context that includes the interpretation of chloramphenicol susceptibility results. A laboratory that observes chloramphenicol resistance in an isolate may consider the possibility of an acetyltransferase enzyme, but it must also consider other resistance mechanisms such as efflux pumps or target modification.

The clinical significance of chloramphenicol acetyltransferases has declined with the reduced use of chloramphenicol in human medicine. However, chloramphenicol is still used in some settings, and the enzymes remain relevant for understanding the resistance mechanisms in certain bacterial populations. The laboratory must be aware of the potential for chloramphenicol resistance when interpreting susceptibility results for this agent.

Macrolide Inactivating Enzymes

Macrolide inactivating enzymes are a group of enzymes that modify macrolide antibiotics such as erythromycin, azithromycin, and clarithromycin. These enzymes include esterases that hydrolyze the macrolide ring and transferases that add a chemical group to the macrolide molecule. The modification prevents the macrolide from binding to the bacterial ribosome, and the antibiotic loses its activity.

The genes encoding macrolide inactivating enzymes are often found in Gram-positive bacteria, including staphylococci and streptococci, and in some Gram-negative bacteria. The enzymes are distinct from the more common macrolide resistance mechanism of target modification, which involves methylation of the ribosomal binding site. The distinction is important because the two mechanisms have different clinical implications and different detection methods.

Laboratory detection of macrolide inactivating enzymes is challenging because the phenotype may be similar to that of target modification. The Clinical and Laboratory Standards Institute provides antimicrobial susceptibility testing context that includes the interpretation of macrolide susceptibility results. A laboratory may observe that an isolate is resistant to erythromycin but susceptible to clindamycin, which suggests the presence of an inducible resistance mechanism. The laboratory must determine whether the resistance is due to an enzyme or to target modification.

The clinical significance of macrolide inactivating enzymes is that they can confer resistance to all macrolides, including the newer agents. The enzymes are also relevant to the treatment of infections caused by organisms such as Mycobacterium abscessus, which can produce macrolide esterases. The laboratory must be aware of the potential for these enzymes when interpreting macrolide susceptibility results.

Tetracycline Inactivating Enzymes

Tetracycline inactivating enzymes are a less common mechanism of tetracycline resistance compared to efflux pumps and ribosomal protection proteins. These enzymes modify the tetracycline molecule by oxidation or hydroxylation, which prevents the antibiotic from binding to the ribosome. The enzymes are found in some Gram-negative bacteria, including Bacteroides species and some Enterobacteriaceae.

The genes encoding tetracycline inactivating enzymes are often present on mobile genetic elements, which allows them to spread among bacterial populations. The enzymes are not as widespread as the efflux and ribosomal protection mechanisms, but they are clinically relevant in certain settings. The laboratory must be aware of the potential for these enzymes when interpreting tetracycline susceptibility results.

Laboratory detection of tetracycline inactivating enzymes is primarily based on phenotypic susceptibility testing. The Clinical and Laboratory Standards Institute provides antimicrobial susceptibility testing context that includes the interpretation of tetracycline susceptibility results. A laboratory that observes tetracycline resistance in an isolate may consider the presence of an inactivating enzyme, but it must also consider the more common mechanisms of efflux and ribosomal protection.

The clinical significance of tetracycline inactivating enzymes is limited because tetracyclines are not the first-line agents for many infections. However, the enzymes are relevant for understanding the resistance of certain bacterial species and for the development of new tetracycline derivatives. The laboratory should be aware of the potential for these enzymes when interpreting susceptibility results for tetracyclines.

Rifampicin ADP-Ribosyltransferases

Rifampicin ADP-ribosyltransferases are enzymes that inactivate rifampicin by transferring an ADP-ribose group to the rifampicin molecule. This modification prevents rifampicin from binding to the bacterial RNA polymerase, and the antibiotic loses its activity. These enzymes are found in Mycobacterium species and some Gram-negative bacteria.

The genes encoding rifampicin ADP-ribosyltransferases are often present on mobile genetic elements, which allows them to spread among bacterial populations. The enzymes are clinically significant because rifampicin is an important agent for the treatment of tuberculosis and other mycobacterial infections. The presence of these enzymes can confer resistance to rifampicin, which complicates the treatment of these infections.

Laboratory detection of rifampicin ADP-ribosyltransferases is primarily based on phenotypic susceptibility testing. The Clinical and Laboratory Standards Institute provides antimicrobial susceptibility testing for mycobacteria, which includes the testing of rifampicin susceptibility. A laboratory that observes rifampicin resistance in a Mycobacterium isolate may consider the presence of an ADP-ribosyltransferase, but it must also consider the more common mechanism of target modification, which is a mutation in the rpoB gene.

The clinical significance of rifampicin ADP-ribosyltransferases is that they can confer resistance to rifampicin and cross-resistance to other rifamycins. The presence of these enzymes is important for the treatment of mycobacterial infections, and the laboratory must be aware of the potential for these enzymes when interpreting rifampicin susceptibility results.

Laboratory Detection and Confirmatory Testing

The detection of antibiotic-inactivating enzymes requires a systematic approach that combines phenotypic and genotypic methods. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing context that helps laboratories to determine the appropriate methods for their specific needs. The laboratory must first perform a standard antimicrobial susceptibility test to determine the minimum inhibitory concentration of the antibiotic for the isolate.

The next step is to determine whether the resistance is due to an inactivating enzyme or to another mechanism. The laboratory may perform a phenotypic confirmatory test, such as the double-disk synergy test for ESBL or the carbapenem inactivation method for carbapenemases. These tests are based on the ability of the enzyme to inactivate the antibiotic, and they provide a rapid and cost-effective method for detecting the enzyme.

The laboratory may also use molecular methods to detect the genes encoding the enzymes. These methods include polymerase chain reaction, DNA sequencing, and whole-genome sequencing. Molecular methods are more sensitive and specific than phenotypic methods, but they are also more expensive and require specialized equipment. The laboratory must weigh the cost and benefit of each method when deciding which to use.

The choice of confirmatory test depends on the organism and the suspected enzyme. For example, a laboratory that identifies a Klebsiella pneumoniae isolate with resistance to carbapenems may perform a carbapenemase detection test. The test may be a phenotypic test, such as the modified carbapenem inactivation method, or a molecular test, such as a PCR for the carbapenemase genes. The result of the test informs the clinical report and the infection control decisions.

Practical Workflow for Enzyme Detection

The practical workflow for detecting antibiotic-inactivating enzymes begins with the isolation of the organism from the clinical specimen. The laboratory must ensure that the organism is pure and that the identification is correct. The American Type Culture Collection provides authenticated biological materials that can be used as quality controls for the identification and susceptibility testing.

The next step is to perform the antimicrobial susceptibility test using a standardized method. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing that includes the methods for disk diffusion, broth dilution, and agar dilution. The laboratory must follow the standards to ensure that the results are accurate and reproducible.

The laboratory then interprets the susceptibility results and determines whether the isolate is resistant to the antibiotic. If the isolate is resistant, the laboratory may perform a confirmatory test to determine whether the resistance is due to an inactivating enzyme. The confirmatory test may be a phenotypic test, such as the double-disk synergy test, or a molecular test, such as a PCR.

The laboratory must document the results of the testing and report them to the clinician. The report should include the susceptibility results, the confirmatory test results, and the interpretation of the results. The report should also include the limitations of the testing, such as the possibility of other resistance mechanisms.

The laboratory must also participate in quality assurance programs to ensure the accuracy of the testing. The American Society for Microbiology provides professional microbiology education and laboratory practice context that can help laboratories to maintain quality. The laboratory must also follow the biosafety guidelines provided by the CDC and NIH to ensure the safety of the laboratory personnel.

Records and Measurements

The laboratory must maintain accurate records of all antimicrobial susceptibility testing and confirmatory testing. The records should include the organism identification, the susceptibility results, the confirmatory test results, and the interpretation of the results. The records should also include the quality control results and the maintenance of the equipment.

The laboratory must measure the minimum inhibitory concentration of the antibiotic for the isolate. The minimum inhibitory concentration is the lowest concentration of the antibiotic that inhibits the visible growth of the organism. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing that includes the interpretation of the minimum inhibitory concentration.

The laboratory must also measure the zone of inhibition for the disk diffusion method. The zone of inhibition is the area around the disk where the antibiotic has inhibited the growth of the organism. The zone of inhibition is measured in millimeters and is interpreted according to the standards.

The laboratory must document the results of the confirmatory tests, including the presence or absence of the enzyme. The results should be recorded in a standardized format that is consistent with the laboratory's quality assurance program. The records should be reviewed by the laboratory director or a qualified supervisor to ensure the accuracy of the results.

Common Failure Patterns in Detection

The detection of antibiotic-inactivating enzymes can fail for several reasons. One common failure is the use of an inappropriate method for the organism or the enzyme. For example, a laboratory that uses a phenotypic test for ESBL may not detect a carbapenemase-producing organism. The laboratory must select the appropriate method for the suspected enzyme.

Another common failure is the misinterpretation of the results. The laboratory may observe a resistance pattern that is consistent with an inactivating enzyme, but the confirmatory test may be negative. This can occur if the enzyme is not expressed under the test conditions or if the enzyme is present but the test is not sensitive enough to detect it.

A third common failure is the lack of quality control. The laboratory must use authenticated strains for quality control, as provided by the American Type Culture Collection. The laboratory must also participate in external quality assurance programs to ensure the accuracy of the testing. The lack of quality control can lead to false results and misinterpretation.

A fourth common failure is the failure to consider other resistance mechanisms. The laboratory may observe a resistance phenotype that is consistent with an inactivating enzyme, but the resistance may be due to another mechanism, such as efflux or target modification. The laboratory must consider all possible mechanisms when interpreting the results.

Limitations of Enzymatic Detection

The detection of antibiotic-inactivating enzymes has several limitations. One limitation is that the phenotypic tests are not always specific for a particular enzyme. For example, the double-disk synergy test for ESBL may also be positive for other beta-lactamases. The laboratory must use the results of the test in combination with other information to determine the specific enzyme.

Another limitation is that the molecular tests may not detect all enzymes. The molecular tests are designed to detect specific genes, and they may not detect novel or variant enzymes. The laboratory must be aware of the limitations of the molecular tests and may need to use additional methods to detect the enzyme.

A third limitation is that the enzyme may be present but not expressed under the test conditions. The enzyme may be inducible, and the test conditions may not induce the enzyme. The laboratory must use the appropriate test conditions to induce the enzyme and to detect the enzyme.

A fourth limitation is that the enzyme may be present but the resistance may be due to another mechanism. The laboratory must consider the complete resistance profile of the organism and the clinical context to determine the mechanism of resistance.

Biosafety and Containment

The laboratory must follow the biosafety guidelines for the handling of organisms that produce antibiotic-inactivating enzymes. The CDC and NIH provide biosafety guidelines for the handling of microorganisms in the laboratory. The guidelines include the use of appropriate containment, personal protective equipment, and decontamination procedures.

The laboratory must assess the risk of the organism and the enzyme. The risk assessment should consider the pathogenicity of the organism, the route of transmission, and the potential for exposure. The laboratory must use the appropriate biosafety level for the organism and the procedures.

The laboratory must also follow the guidelines for the decontamination of the laboratory and the equipment. The decontamination must be performed to prevent the spread of the organism and the enzyme. The laboratory must use the appropriate disinfectants and the appropriate procedures for the decontamination.

The laboratory must also follow the guidelines for the disposal of the waste. The waste must be disposed of in a manner that prevents the spread of the organism and the enzyme. The laboratory must use the appropriate waste disposal procedures and the appropriate containers.

Quality Controls and Assurance

The laboratory must implement a quality assurance program to ensure the accuracy of the enzyme detection. The program should include the use of quality control strains, the participation in external quality assurance programs, and the documentation of the results. The American Type Culture Collection provides authenticated biological strains that can be used as quality controls.

The laboratory must use the quality control strains to verify the performance of the testing. The quality control strains should be tested with the same methods as the clinical isolates. The results of the quality control should be within the expected range, and the laboratory must investigate any out-of-range results.

The laboratory must participate in external quality assurance programs to compare the results of the laboratory with the results of other laboratories. The external quality assurance programs provide a measure of the accuracy of the laboratory and the laboratory must use the results to improve the quality of the testing.

The laboratory must also document the quality assurance activities and the results. The documentation should include the quality control results, the external quality assurance results, and the corrective actions taken. The documentation should be accessible and should be reviewed by the laboratory director.

Professional Escalation Criteria

The laboratory must have a process for the escalation of the results that are unusual or that require the attention of a specialist. The escalation should be based on the clinical significance of the result and the potential for the impact on the patient.

The laboratory should escalate the results when the isolate is resistant to the last-resort antibiotics, such as carbapenems or colistin. The laboratory should also escalate the results when the isolate is resistant to the antibiotics that are used for the treatment of the infection. The escalation should include the notification of the clinician and the infection control team.

The laboratory should also escalate the results when the confirmatory test is positive for a carbapenemase or an ESBL. The escalation should include the notification of the clinician and the infection control team. The escalation should also include the recommendation for the appropriate infection control measures.

The laboratory should also escalate the results when the isolate is from a patient who is at high risk for the infection, such as a patient in the intensive care unit or a patient with a compromised immune system. The escalation should include the notification of the clinician and the infection control team.

Limitations of the Evidence

The evidence for the enzymatic inactivation of antibiotics is based on the scientific literature and the official sources. The World Health Organization provides the global context for antimicrobial resistance, and the Clinical and Laboratory Standards Institute provides the standards for the antimicrobial susceptibility testing. The American Society for Microbiology provides the professional context for the laboratory practice.

The evidence for the specific enzymes is based on the scientific literature, and the laboratory must be aware of the limitations of the evidence. The evidence may not be complete for all enzymes, and the laboratory must use the evidence in the context of the clinical situation.

The laboratory must also be aware of the limitations of the testing methods. The phenotypic methods may not be reliable for all enzymes, and the molecular methods may not detect all enzymes. The laboratory must use the methods in the context of the clinical situation and the laboratory must interpret the results with caution.

The laboratory must also be aware of the limitations of the quality assurance. The quality assurance program may not detect all errors, and the laboratory must use the quality assurance in the context of the laboratory's quality program.

Decision Framework for Selecting Confirmatory Tests by Enzyme Family

Choosing the wrong confirmatory test wastes time, consumes reagents, and can delay the reporting of a clinically significant resistance mechanism. A structured decision framework helps the laboratory move from a resistance phenotype to a specific enzyme hypothesis and then to the appropriate confirmatory test. The framework below organizes the decision process into four sequential checkpoints that the laboratory can apply to any isolate with a suspected inactivating enzyme.

Checkpoint One: Define the Resistance Phenotype

The first checkpoint requires the laboratory to record the complete susceptibility profile of the isolate, beyond the single antibiotic that triggered the investigation. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing context that defines how minimum inhibitory concentrations and disk diffusion zones are interpreted. The laboratory should document the results for every antibiotic in the testing panel, including those that appear susceptible.

The resistance phenotype is the pattern of susceptible and resistant results across the panel. This pattern narrows the list of candidate enzymes. For example, an Enterobacterales isolate that is resistant to ampicillin and first-generation cephalosporins but susceptible to third-generation cephalosporins suggests a narrow-spectrum beta-lactamase. An isolate that is resistant to third-generation cephalosporins and aztreonam but susceptible to cefoxitin suggests an extended-spectrum beta-lactamase. An isolate that is resistant to carbapenems suggests a carbapenemase, but the laboratory must also consider the possibility of a cephalosporinase combined with porin loss.

The laboratory should record the phenotype before performing any confirmatory test. This record becomes the baseline against which the confirmatory test result is interpreted. A confirmatory test that contradicts the phenotype should be repeated or investigated, because the discrepancy may indicate a testing error or an unusual enzyme.

Checkpoint Two: Match the Phenotype to an Enzyme Family

The second checkpoint requires the laboratory to compare the recorded phenotype against the substrate profiles of the major enzyme families. The table in the At a Glance section provides the primary substrates and typical organisms for each family. The laboratory should use this table as a starting point, but it must also consider the local epidemiology and the organism species.

The organism identification is a critical filter. For example, a carbapenem-resistant Acinetobacter baumannii isolate is more likely to produce an OXA-type carbapenemase than a Klebsiella pneumoniae carbapenemase. A carbapenem-resistant Enterobacterales isolate may produce a KPC, NDM, VIM, IMP, or OXA-48-type enzyme, and the choice of confirmatory test depends on which enzyme is suspected. The American Type Culture Collection provides authenticated biological materials that can be used as quality controls for the identification and the susceptibility testing.

The laboratory should also consider the specimen source and the patient history. An isolate from a patient who has recently traveled to a region with high prevalence of a specific carbapenemase may warrant a targeted molecular test for that enzyme. An isolate from a patient with no travel history may be more likely to produce the locally endemic enzyme. The laboratory should document these contextual factors in the record.

Checkpoint Three: Select the Confirmatory Test

The third checkpoint is the selection of the confirmatory test. The laboratory must choose between phenotypic and molecular methods based on the enzyme family, the organism, the laboratory capacity, and the urgency of the result. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing that includes the methods for the confirmatory testing.

For beta-lactamases, the laboratory may use a phenotypic test such as the double-disk synergy test for extended-spectrum beta-lactamases or the modified carbapenem inactivation method for carbapenemases. These tests are cost-effective and do not require specialized equipment, but they may take 18 to 24 hours to produce a result. Molecular tests such as polymerase chain reaction for the carbapenemase genes are faster and more specific, but they require the equipment and the expertise.

For aminoglycoside modifying enzymes, the laboratory typically relies on the phenotypic susceptibility pattern instead of a specific confirmatory test. The pattern of resistance to gentamicin but susceptibility to amikacin is often sufficient to infer the presence of a specific modifying enzyme. Molecular tests for the aminoglycoside modifying enzyme genes are available, but they are not routinely performed in most clinical laboratories.

For chloramphenicol acetyltransferases, macrolide esterases, tetracycline inactivating enzymes, and rifampicin ADP-ribosyltransferases, the laboratory typically relies on the phenotypic susceptibility result. Confirmatory tests for these enzymes are less commonly available and are often performed only in reference laboratories. The laboratory should consult the Clinical and Laboratory Standards Institute standards for the specific testing recommendations.

Checkpoint Four: Interpret the Result and Document the Decision

The fourth checkpoint is the interpretation of the confirmatory test result and the documentation of the decision. The laboratory must interpret the result in the context of the phenotype and the organism. A positive confirmatory test confirms the presence of the enzyme, but it does not exclude the presence of other resistance mechanisms. A negative confirmatory test does not exclude the presence of the enzyme, because the enzyme may not be expressed under the test conditions or the test may not be sensitive enough to detect it.

The laboratory must document the decision process, including the phenotype, the suspected enzyme family, the confirmatory test selected, and the result. This documentation is essential for the quality assurance program and for the review by the laboratory director. The documentation should also include the limitations of the testing, such as the possibility of a novel enzyme that is not detected by the test.

The laboratory should also document the clinical significance of the result. A carbapenemase-producing organism requires infection control measures and a consultation with the clinical team. An extended-spectrum beta-lactamase-producing organism may require a change in the antibiotic therapy. The laboratory should communicate the result to the clinician and the infection control team according to the escalation criteria.

Record System for Enzyme Detection Decisions

The laboratory should maintain a record system that captures the decision framework for each isolate that undergoes confirmatory testing. The record should include the following fields:

The organism identification and the specimen source
The antimicrobial susceptibility profile, including the minimum inhibitory concentrations or the zone diameters
The suspected enzyme family and the rationale for the suspicion
The confirmatory test selected and the reason for the selection
The confirmatory test result and the interpretation
The final report to the clinical team
The quality control results for the confirmatory test

The record system should be reviewed periodically to identify patterns in the enzyme detection process. The laboratory may find that a particular confirmatory test is frequently negative for a specific phenotype, which may indicate that the test is not appropriate for the local epidemiology. The laboratory may also find that a particular enzyme is more common in a specific specimen source, which may inform the selection of the confirmatory test in the future.

The American Society for Microbiology provides professional microbiology education and laboratory practice context that can help the laboratory to develop and maintain the record system. The laboratory should also participate in external quality assurance programs to compare the results of the confirmatory testing with the results of other laboratories.

Troubleshooting Discrepant Results

A discrepant result occurs when the confirmatory test does not match the resistance phenotype. The laboratory must investigate the discrepancy before reporting the result. The following troubleshooting steps are recommended.

First, the laboratory should verify the organism identification. A misidentified organism can lead to an incorrect enzyme hypothesis and an inappropriate confirmatory test. The laboratory should repeat the identification using a different method or a different biochemical test.

Second, the laboratory should verify the susceptibility testing result. The laboratory should repeat the susceptibility test to confirm the resistance phenotype. The laboratory should also check the quality control results for the susceptibility test to ensure that the test was performed correctly.

Third, the laboratory should consider the possibility of a mixed culture. A mixed culture may contain two organisms with different resistance mechanisms, which can produce a confusing phenotype. The laboratory should re-isolate the organism and repeat the testing on a pure culture.

Fourth, the laboratory should consider the possibility of an inducible enzyme. Some enzymes are not expressed under the standard test conditions, and the confirmatory test may be negative even though the enzyme is present. The laboratory should use the appropriate induction conditions for the suspected enzyme.

Fifth, the laboratory should consider the possibility of a novel or variant enzyme. The molecular tests are designed to detect specific genes, and they may not detect a novel enzyme. The laboratory should consider the use of whole-genome sequencing if the phenotype is consistent with an enzyme but the confirmatory test is negative.

The laboratory should document the investigation of the discrepant result and the final interpretation. The documentation should include the steps taken to investigate the discrepancy and the reason for the final interpretation. The laboratory should also report the discrepancy to the laboratory director or the quality assurance program.

Biosafety Considerations for Confirmatory Testing

The confirmatory testing for antibiotic-inactivating enzymes involves the handling of organisms that may be resistant to multiple antibiotics. The laboratory must follow the biosafety guidelines for the handling of these organisms. The CDC and NIH provide biosafety guidelines for the laboratory and the containment of the microorganisms. The guidelines include the use of the appropriate containment, the personal protective equipment, and the decontamination procedures.

The laboratory must also follow the guidelines for the transport of the isolates to the reference laboratory for the confirmatory testing. The transport must be performed in a manner that prevents the exposure of the personnel and the environment. The laboratory must use the appropriate transport containers and the appropriate labeling.

Professional Escalation Criteria for Confirmatory Testing

The laboratory should escalate the results when the confirmatory test is positive for a carbapenemase or an extended-spectrum beta-lactamase. The escalation should include the notification of the clinician and the infection control team. The escalation should also include the recommendation for the appropriate infection control measures.

The laboratory should also escalate the results when the confirmatory test is negative but the phenotype is consistent with an enzyme. The escalation should include the notification of the clinician and the infection control team. The escalation should also include the recommendation for the additional testing, such as whole-genome sequencing.

The laboratory should also escalate the results when the isolate is resistant to the last-resort antibiotics, such as carbapenems or colistin. The escalation should include the notification of the clinician and the infection control team. The escalation should also include the recommendation for the appropriate infection control measures.

Frequently Asked Questions

What is the difference between enzymatic inactivation and other antibiotic resistance mechanisms?

Enzymatic inactivation is a resistance mechanism where the bacterium produces an enzyme that chemically modifies or degrades the antibiotic molecule. Other mechanisms include target modification, where the antibiotic target is altered, and efflux pumps, which remove the antibiotic from the cell. Enzymatic inactivation is distinct because the antibiotic is the substrate for the enzyme, and the reaction directly destroys the antibiotic activity.

How do I choose the appropriate confirmatory test for a suspected enzyme?

The choice of the confirmatory test depends on the organism and the suspected enzyme. The laboratory should consider the resistance phenotype, the organism identification, and the clinical context. The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing that includes the methods for the confirmatory testing. The laboratory should also consider the cost and the availability of the test.

What is the role of the Clinical and Laboratory Standards Institute in antimicrobial susceptibility testing?

The Clinical and Laboratory Standards Institute provides standards-based antimicrobial susceptibility testing that includes the methods for the testing and the interpretation of the results. The standards are used by laboratories to ensure the accuracy and the reproducibility of the testing. The laboratory should use the standards to guide the testing and the interpretation of the results.

What is the role of the American Type Culture Collection in the laboratory?

The American Type Culture Collection provides authenticated biological strains that can be used as quality controls for the identification and the testing. The strains are used to verify the performance of the testing and to ensure the accuracy of the results. The laboratory should use the authenticated strains for the quality control.

What is the role of the World Health Organization in antimicrobial resistance?

The World Health Organization provides the global context for antimicrobial resistance, including the definitions, the surveillance, and the stewardship. The WHO identifies antimicrobial resistance as a global public health concern and provides the guidance for the prevention and the control of the resistance. The laboratory should be aware of the global context of the resistance.

What is the role of the CDC and NIH in the laboratory biosafety?

The CDC and NIH provide the biosafety guidelines for the laboratory and the containment of the microorganisms. The guidelines include the use of the appropriate containment, the personal protective equipment, and the decontamination. The laboratory should follow the guidelines to ensure the safety of the laboratory personnel.

What is the role of the American Society for Microbiology in the laboratory practice?

The American Society for Microbiology provides the professional context for the laboratory practice, including the education and the resources. The ASM provides the guidance for the laboratory practice and the workforce. The laboratory should use the ASM resources to ensure the quality of the laboratory practice.

What is the role of the FDA in the laboratory methods?

The FDA provides the Bacteriological Analytical Manual for the official food microbiology methods and the quality context. The manual provides the methods for the detection and the identification of the microorganisms in the food. The laboratory should use the manual for the food microbiology testing.

Using the Evidence

Source	Best use in this topic	Important limitation
Biosafety in Microbiological and Biomedical Laboratories	official guidance	Check the linked page for current local requirements
Microbiology Resources	official guidance	Check the linked page for current local requirements
Antimicrobial Resistance	official guidance	Check the linked page for current local requirements

Related Bacteriology Guides

References and Further Reading

Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
Microbiology Resources. American Society for Microbiology.
Antimicrobial Resistance. World Health Organization.
Bacteriological Analytical Manual. U.S. Food and Drug Administration.
Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
Culture Collections. American Type Culture Collection.
NCBI Pathogen Detection. National Center for Biotechnology Information.
Molecular Mechanisms of Drug Resistance in Staphylococcus aureus.. International journal of molecular sciences, 2022.
Mechanisms of Action of Probiotics.. Advances in nutrition (Bethesda, Md.), 2019.
Mechanisms of antibiotic resistance in Staphylococcus aureus.. Future microbiology, 2007.
Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria.. Antibiotics (Basel, Switzerland), 2024.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.